This inventor holds 1 USPTO granted patent. Top assignee: Nurix Therapeutics, Inc.. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: Michael Lotze: Innovator in Immune Cell Expansion
Introduction
Michael Lotze is a prominent inventor based in San Francisco, CA. He has made significant contributions to the field of immunotherapy, particularly through his innovative work on CBL inhibitors. His research focuses on enhancing the efficacy of cell-based immunotherapeutics, which has the potential to revolutionize cancer treatment.
Latest Patents
Michael Lotze holds a patent for "CBL inhibitors and compositions for expansion of immune cells." This patent discloses methods and compositions using novel Cbl inhibitors that enhance the expansion of immune cells. The goal is to increase the efficacy of cell-based immunotherapeutics, providing new avenues for treatment.
Career Highlights
Lotze is currently associated with Nurix Therapeutics, Inc., where he continues to advance his research in immunotherapy. His work has garnered attention for its potential impact on the treatment of various diseases, particularly cancer.
Collaborations
Michael Lotze collaborates with notable colleagues, including Jennifa Gosling and Arthur T Sands. Their combined expertise contributes to the innovative research being conducted at Nurix Therapeutics.
Conclusion
Michael Lotze's contributions to the field of immunotherapy through his patent and work at Nurix Therapeutics highlight his role as a key innovator in enhancing immune cell expansion. His research promises to advance the effectiveness of cell-based treatments, paving the way for future breakthroughs in cancer therapy.